Hamza Hassan

MD
Hematologic Oncology

Cancers Treated:

Multiple Myeloma

Specializing In:

Plasma Cell Disorders Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Myeloma Light Chain Amyloidosis POEMS Syndrome Waldenstrom's Macroglobulinemia Cryoglobulinemia Bone Marrow Transplantation/Stem Cell Transplantation Immunotherapy Cellular Therapy

Research Interests:

Cellular therapy High-risk Multiple Myeloma AL amyloidosis Phase I trials CAR T-cells Fraility Patient-reported outcomes

About Hamza Hassan

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Medicine, Myeloma and Amyloidosis Division

Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

  • Assistant Professor of Medicine

Background

Education and Training:

  • MBBS - Rawalpindi Medical College, University of Health Sciences, Lahore, Pakistan

Fellowship:

  • Boston University School of Medicine/Boston Medical Center, Boston, MA

Board Certification:

  • American Board of Internal Medicine

Professional Memberships:

  • American Society of Hematology
  • American Society of Medical Oncology
  • American Society of Transplant and Cellular Therapy

Honors & Awards:

  • Research Travel Award; Amyloidosis Research Consortium
  • Best Clinical Poster Award, Evan’s Day, BUSM Institutional Award
  • FDA/ASCO Fellows' Workshop

Publications

Full Publications list on PubMed
  • DuMontier C, La J, Bihn J, Corrigan J, Yildirim C, Dharne M, Hassan H, Yellapragada S, Abel GA, Gaziano JM, Do NV, Brophy M, Kim DH, Munshi NC, Fillmore NR, Driver JA. More intensive therapy has a better effect for frail parents with multiple myeloma. Blood Adv. 2023 Oct 24;7(20):6275-6284. doi: 10.1182/bloodadvances.2023011019. PMID: 37582048; PMCID: PMC10589796.
  • Hassan H, Szalat R. Genetic Predictors of Mortality in Patients with Multiple Myeloma. Appl Clin Genet. 2021 Apr 29;14:241-254. doi: 10.2147/TACG.S262866. PMID: 33953598; PMCID: PMC8092627.
  • Hassan H, Verma K, Ferri G, Brauneis D, Quillen K, Sloan JM, Sanchorawala V, Edwards CV. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Transplant Cell Ther. 2022 Nov;28(11):761.e1-761.e7. doi: 10.1016/j.jtct.2022.08.007. Epub 2022 Aug 12. PMID: 35970300.
  • Hassan H, Anwer F, Javaid A, Hashmi H. Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis. Crit Rev Oncol Hematol. 2021 Sep;165:103435. doi: 10.1016/j.critrevonc.2021.103435. Epub 2021 Jul 31. PMID: 34343658.
  • Edwards CV, Hassan H, Yildirim C, Ferri G, Verma KP, Murray Horwitz ME, Fillmore NR, Munshi NC. Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv. 2023 Feb 28;7(4):482-490. doi: 10.1182/bloodadvances.2022008021. PMID: 36409606; PMCID: PMC9979755.
  • Hassan H, Sanchorawala V. Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs. Hemato. 2022 Jan 4;3(1):38-46.